Comparative Pharmacology
Head-to-head clinical analysis: GABAPENTIN ENCARBIL versus QUDEXY XR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GABAPENTIN ENCARBIL versus QUDEXY XR.
GABAPENTIN ENCARBIL vs QUDEXY XR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Gabapentin encarbil is a prodrug of gabapentin, which binds to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system, reducing calcium influx and inhibiting neurotransmitter release.
Stabilizes neuronal membranes and inhibits repetitive firing of action potentials via blockade of voltage-gated sodium channels; also enhances GABAergic activity and inhibits glutamate release.
Oral gabapentin encarbil 600 mg once daily with evening meal, titrated based on response and tolerability, maximum 1200 mg once daily. Alternatively, 600 mg twice daily may be used; maximum 2400 mg/day.
Initial dose 25 mg orally twice daily; titrate by 25-50 mg/day every 1-2 weeks to target dose of 200-400 mg/day in two divided doses. Maximum 400 mg/day.
None Documented
None Documented
The terminal elimination half-life of gabapentin derived from gabapentin encarbil is approximately 5-7 hours in patients with normal renal function. This half-life is prolonged in patients with renal impairment (up to 132 hours in anuria). Clinically, steady-state concentrations are achieved within 1-2 days. Twice-daily dosing is effective due to sustained exposure from the prodrug formulation.
Terminal elimination half-life is approximately 70-90 hours after multiple dosing, supporting twice-daily dosing; requires slow titration to steady state (2-3 weeks).
Renal: Gabapentin encarbil is a prodrug of gabapentin. Following absorption, it is rapidly hydrolyzed to gabapentin. Gabapentin is primarily excreted unchanged in urine via glomerular filtration. Approximately 80-90% of a dose is recovered in urine as gabapentin, with the remainder as metabolites and minor amounts (≤1%) in feces. Biliary excretion is negligible.
Renal: approximately 70% as unchanged drug; fecal: approximately 20%; biliary: minor (<5%).
Category A/B
Category C
Anticonvulsant
Anticonvulsant